Long-term effects of glucosamine sulphate on osteoarthritis progression: a three-year, randomised, placebo-controlled clinical trial
Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O
Published in The Lancet
Methodology
Three-year randomised, double-blind, placebo-controlled trial of 1500 mg/day glucosamine sulphate in knee osteoarthritis with radiographic joint-space measurement
Key Findings
Placebo patients lost joint space (mean -0.31 mm) while glucosamine patients had no significant loss; WOMAC symptom scores improved modestly with glucosamine.
Conclusions
Glucosamine sulphate 1500 mg/day slowed radiographic progression and modestly improved symptoms over three years.
Limitations
Single manufacturer's preparation; industry funded; radiographic significance debated.
Supplements Studied
Patients on placebo had a progressive joint-space narrowing, with a mean joint-space loss of -0.31 mm, whereas there was no significant joint-space loss in patients on glucosamine sulphate.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.